One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model

Safe and effective vaccines will provide essential medical countermeasures to tackle the COVID-19 pandemic. Here, we assessed the safety, immunogenicity and efficacy of the intradermal delivery of INO-4800, a synthetic DNA vaccine candidate encoding the SARS-CoV-2 spike protein in the rhesus macaque...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooch, Karen E., Smith, Trevor R.F., Salguero, Francisco J., Fotheringham, Susan A., Watson, Robert J., Dennis, Mike J., Handley, Alastair, Humphries, Holly E., Longet, Stephanie, Tipton, Tom, Sarfas, Charlotte, Sibley, Laura, Slack, Gillian S., Rayner, Emma, Ryan, Kathryn A., Schultheis, Katherine, Ramos, Stephanie J., White, Andrew, Charlton, Sue, Sharpe, Sally A., Gleeson, Fergus, Humeau, Laurent M., Hall, Yper, Broderick, Kate E., Carroll, Miles W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220992/
https://www.ncbi.nlm.nih.gov/pubmed/34253420
http://dx.doi.org/10.1016/j.vaccine.2021.06.057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220992/
https://www.ncbi.nlm.nih.gov/pubmed/34253420
http://dx.doi.org/10.1016/j.vaccine.2021.06.057

Ejemplares similares